Method Developments and Validation of Atorvastatin and Clopidogrel in Tablet dosage form by Miceller Liquid Chromatography

DEVELOPMENT OF MLC METHOD FOR CARDIAC TABLETS

Abstract

To avoid heart attacks and strokes, a combination of atorvastatin and clopidogrel is used. A cholesterol-producing enzyme is inhibited by the lipid-lowering medication atorvastatin. Atorvastatin helps in reducing the level of bad cholesterol, Low Density Lipoprotein (LDL) and increasing good cholesterol level, High Density Lipoprotein (HDL) in our body. An antiplatelet drug called clopidogrel reduces the risk of dangerous blood clots by preventing platelets from adhering to one another. A novel, straightforward, and precise approach was used to estimate atorvastatin and clopidogrel quantitatively in tablet formulation by Micellar Liquid Chromatography (MLC). The MLC is a green and eco-friendly technique in Chromatography where surfactant solutions played the role as the eluent above the Critical Miceller Concentration (CMC).The separation of drug formulation was carried out by Reversed Phase Liquid Chromatography (RP-HPLC) using a Deoxyprobe C18 column (4.6 × 250 mm, 5 µm) with a mobile phase that contained 0.12M SDS and 10% Propanol-2 at a pH 3.7 maintained by o-Phosphoric Acid. The separation was performed at room temperature with an elution rate of 1.1mL/minat 220 nm. The retention time of atorvastatin is 2.3 while that of clopidogrel is 3.9 min. According to the schedule V of the drug and Cosmetic Act, the percentage composition of the sample under analysis ranged from 90 to 110%. The suggested procedure was in agreement with ICH requirements. In addition, the method was easy to use, affordable, safe, and non-harmful to the environment. It can be used for repetitive measurable estimation of atorvastatin and clopidogrel in tablets.